EPS for Interpace Diagnostics Group, Inc. (IDXG) Expected At $-0.13

March 15, 2018 - By Adrian Mccoy

 EPS for Interpace Diagnostics Group, Inc. (IDXG) Expected At $ 0.13

Analysts expect Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) to report $-0.13 EPS on April, 4.They anticipate $3.38 EPS change or 104.00 % from last quarter’s $3.25 EPS. After having $-0.15 EPS previously, Interpace Diagnostics Group, Inc.’s analysts see -13.33 % EPS growth. The stock increased 1.91% or $0.02 during the last trading session, reaching $1.06. About 398,785 shares traded. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has declined 18.90% since March 15, 2017 and is downtrending. It has underperformed by 35.60% the S&P500.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $28.46 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

More notable recent Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) news were published by: Globenewswire.com which released: “Interpace Diagnostics to Present at the 6th Annual Liolios Gateway Conference …” on August 31, 2017, also Globenewswire.com with their article: “Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays” published on February 12, 2018, Seekingalpha.com published: “Interpace Diagnostics Group’s (IDXG) CEO Jack Stover on Q3 2017 Results …” on November 13, 2017. More interesting news about Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were released by: Globenewswire.com and their article: “Interpace Diagnostics Announces New CPT Code for Reimbursement of Molecular …” published on September 11, 2017 as well as Globenewswire.com‘s news article titled: “Interpace Diagnostics Announces Increased Reimbursement for ThyGenX®” with publication date: October 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: